NCT02376075 - Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Arterial HypertensionAlbuminuria

Interventions

DRUG

Linagliptin

Intake of tablets containing 5 mg Linagliptin, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks

DRUG

Placebo

Intake of Placebo, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks

Trial Locations (1)

Profil Mainz GmbH & Co. KG, Mainz